文献速递血栓与止血

难治性免疫性血小板减少症的诊断与联合治疗

Identifying and treating refractory ITP: difficulty in diagnosis and role of combination treatment.
PubMed 文献 · Blood · 2020-01-01

本文综述难治性ITP的诊断挑战与联合治疗策略。难治性患者可能诊断并非真正ITP或疾病难以管理;对治疗的反应是唯一确诊依据,但难治患者对一线治疗无反应。当前联合治疗较TPO和利妥昔单抗前时代更有效;TPO药物虽单药失败,仍可能是关键组分。

要点

  • 难治性ITP诊断需排除其他疾病,治疗反应是唯一确诊依据。
  • 当前联合治疗较前TPO/利妥昔单抗时代更有效。
  • TPO药物单药失败后仍可能是联合治疗的关键组分。

核心结论

  • 难治性ITP是复杂疾病,精确诊断与有效联合治疗同等重要。
  • 当前联合治疗较前TPO和利妥昔单抗时代更有效。
  • TPO药物虽单药失败,仍可能是联合治疗的关键组分。

研究设计与样本

  • 综述,评估难治性ITP的诊断考虑与联合治疗。
  • 联合方案按TPO和利妥昔单抗前时代与当前时代划分。

主要发现

  • 难治性患者可能诊断并非真正ITP或疾病难以管理。
  • ITP为排除性诊断,无特异性检测确认,治疗反应是唯一确诊依据。
  • 难治患者对一线或其他治疗无反应,故无诊断确认。
  • 当前治疗似乎更有效,但难治定义若包括对TPO药物反应不足则病情更重。
  • 难治性ITP生物学 largely 未探索,涉及寡克隆性、淋巴细胞泵等。

关键数值与推荐

  • 难治性定义若包括对TPO药物反应不足,描述更严重难治疾病。
  • 新治疗如雷帕霉素、fostamatinib、FcRn、BTK抑制剂可能有用。

临床怎么用

  • 难治性ITP需仔细排除其他诊断,治疗反应可辅助确诊。
  • 联合治疗可考虑TPO药物作为关键组分,即使单药失败。
  • 新机制药物可能成为未来联合治疗组分。

局限性

  • 难治性ITP的生物学 largely 未探索。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Immune thrombocytopenia (ITP) is the most common acquired thrombocytopenia after chemotherapy-induced thrombocytopenia. Existing guidelines describe the management and treatment of most patients who, overall, do well, even if they present with chronic disease, and they are usually not at a high risk for bleeding; however, a small percentage of patients is refractory and difficult to manage. Patients classified as refractory have a diagnosis that is not really ITP or have disease that is difficult to manage. ITP is a diagnosis of exclusion; no specific tests exist to confirm the diagnosis. Response to treatment is the only affirmative confirmation of diagnosis. However, refractory patients do not respond to front-line or other treatments; thus, no confirmation of diagnosis exists. The first section of this review carefully evaluates the diagnostic considerations in patients with refractory ITP. The second section describes combination treatment for refractory cases of ITP. The reported combinations are divided into the era before thrombopoietin (TPO) and rituximab and the current era. Current therapy appears to have increased effectiveness. However, the definition of refractory, if it includes insufficient response to TPO agents, describes a group with more severe and difficult-to-treat disease. The biology of refractory ITP is largely unexplored and includes oligoclonality, lymphocyte pumps, and other possibilities. Newer treatments, especially rapamycin, fostamatinib, FcRn, and BTK inhibitors, may be useful components of future therapy given their mechanisms of action; however, TPO agents, notwithstanding failure as monotherapy, appear to be critical components. In summary, refractory ITP is a complicated entity in which a precise specific diagnosis is as important as the development of effective combination treatments.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Miltiadous O, Hou M, Bussel JB, et al. Identifying and treating refractory ITP: difficulty in diagnosis and role of combination treatment. Blood. 2020. PMID: 31756253. doi:10.1182/blood.2019003599

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。